Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.43 USD
Change Today -0.03 / -2.05%
Volume 69.6K
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

pharmathene inc (PIP) Snapshot

Open
$1.46
Previous Close
$1.46
Day High
$1.48
Day Low
$1.42
52 Week High
09/10/14 - $2.59
52 Week Low
08/26/15 - $1.38
Market Cap
91.8M
Average Volume 10 Days
112.7K
EPS TTM
$-0.12
Shares Outstanding
64.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMATHENE INC (PIP)

pharmathene inc (PIP) Related Businessweek News

No Related Businessweek News Found

pharmathene inc (PIP) Details

PharmAthene, Inc., a biodefense company, develops and commercializes medical counter measures against biological and chemical threats in the United States. Its product candidates include SparVax, a recombinant protective antigen anthrax vaccine for post-exposure prophylaxis in conjunction with antibiotics and general use prophylaxis; Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax; and recombinant butyrylcholinesterase bioscavenger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds comprising nerve gases and pesticides. The company serves the Biomedical Advanced Research and Development Authority, Chemical Biological Medical Systems, and the National Institute of Allergy and Infectious Diseases. It has collaboration with Bristol-Myers Squibb for developing Valortim; and strategic alliance with Nanotherapeutics, Inc. to develop biodefense programs. The company is headquartered in Annapolis, Maryland.

35 Employees
Last Reported Date: 03/11/15

pharmathene inc (PIP) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pharmathene inc (PIP) Key Developments

PharmAthene, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

PharmAthene, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported contract revenue of $1,149,570 against $3,658,933 a year ago. Loss from operations was $1,964,867 against $1,169,871 a year ago. Net loss before income taxes was $2,329,864 against $445,788 a year ago. Net loss was $2,340,932 against $439,120 a year ago. Basic and diluted net loss per share was $0.04 against $0.01 a year ago. The decrease in revenue was primarily due to an overall reduction in development activity in the company's biodefense programs, including the de-scoping of the SparVax® anthrax vaccine contract. For the six months, the company reported contract revenue of $8,218,316 against $7,401,458 a year ago. Loss from operations was $803,783 against $3,571,737 a year ago. Net loss before income taxes was $846,664 against $2,674,523 a year ago. Net loss was $2,340,932 against $439,120 a year ago. Basic and diluted net loss per share was $0.01 against $0.05 a year ago.

PharmAthene to Develop New Anthrax Vaccine with Immunovaccine

PharmAthene has entered into an exclusive agreement with vaccine and immunotherapy company Immunovaccine to co-develop an commercialize an Anthrax vaccine formulated using Immunovaccine's proprietary DepoVax vaccine platform.

PharmAthene, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

PharmAthene, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported contract revenue of $7,068,746 against $3,742,525 a year ago. Income from operations was $1,161,084 against loss from operations was $2,401,866 a year ago. Net income before provision for income taxes was $1,483,200 against net loss before provision for income taxes was $2,228,735 a year ago. Net income was $1,463,395 or $0.02 basic and diluted per share against net loss was $2,258,440 or $0.04 basic and diluted per share a year ago. The increase was primarily due to revenue recognition of a one-time payment of $5.8 million related to the audit by BARDA of indirect costs or rates charged by PharmAthene on the SparVax® contract for the years 2008 through 2013. The $5.8 million represented the difference between actual rates (i.e., actual cost to PharmAthene) and the provisional rates used to calculate previously billed and recognized revenue.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PIP:US $1.43 USD -0.03

PIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Achillion Pharmaceuticals Inc $7.76 USD +0.25
Bavarian Nordic A/S kr292.50 DKK -1.50
Bioporto A/S kr2.54 DKK +0.08
Celldex Therapeutics Inc $15.36 USD +0.25
Chimerix Inc $50.48 USD -0.02
View Industry Companies
 

Industry Analysis

PIP

Industry Average

Valuation PIP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.3x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMATHENE INC, please visit www.pharmathene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.